EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer

Emmanuelle Samalin iD, Hélène Senellart, Simon Thezenas iD, Stéphane Jacquot, Stephen Ellis, Faiza Khemissa Akouz iD, Catherine Fiess iD, Mohamed Ramdani, Fabienne Portales iD, Eric Assenat iD, Marc Ychou iD, Laurent Mineur und 1 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag006 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2026. Verfasst von Emmanuelle Samalin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical oncology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier 34298 Cedex 5, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Thiophenes. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Second-line FOLFOX-bevacizumab treatment is effective in metastatic colorectal cancer (mCRC) treatment after irinotecan-based chemotherapy failure. First- or second-line raltitrexed-oxaliplatin (TOMOX) treatment has an acceptable toxicity profile in mCRC. The aim of this study was to evaluate TOMOX-bevacizumab combination as a second-line treatment.

Methods

The BEVATOMOX study was a non-comparative, prospective, randomized, open-label, multicentric phase II trial. Patients with histologically proven unresectable mCRC and progressive metastatic disease after irinotecan-based chemotherapy were randomized (1:2) to receive mFOLFOX6-bevacizumab (control arm, bevacizumab 5 mg/kg, mFOLFOX6 D1 = D15, 12 cycles) or TOMOX-bevacizumab (experimental arm, bevacizumab 7.5 mg/kg, raltitrexed 3 mg/m2 based on creatinine clearance, oxaliplatin 130 mg/m2, D1 = D21, 8 cycles). The primary endpoint was 6-month progression-free survival (6PFS). Target enrollment was 30 and 62 patients in the control and experimental arms, respectively.

Results

Eighty-three patients (median age 66 [48-82] years, 63.9% male, 54.2% KRAS mt) were included: 33 in the control and 50 in the experimental arms. The 6PFS rate and median overall survival were 51.5 (95% CI, 36-67) and 11.1 months (9.5-16.4) in the control arm vs 38 (95% CI, 26-51) and 9.3 (5.7-11.6) months in the experimental arm. In the experimental arm, left-sided tumors had a longer overall survival vs right-sided (11.6 vs 4.6 months, P < .001). Grade 3-4 toxicities (mucositis, neutropenia, febrile neutropenia, paresthesia, hand-foot syndrome) were similar between arms.

Conclusion

The TOMOX-Bev combination is a feasible second-line mCRC treatment with an acceptable toxicity profile. Recruitment failure prevents efficacy conclusions, but TOMOX-Bev may be an alternative if fluropyrimidines are contraindicated. Trial registration number ClinicalTrials.gov, NCT01532804.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBevacizumabAntineoplastic Combined Chemotherapy ProtocolsThiophenesHumansMaleMiddle AgedFemaleQuinazolinesOxaliplatinAgedFluorouracilOrganoplatinum CompoundsLeucovorinNeoplasm Metastasis

Stichwörter der Autor:innen

bevacizumabmetastatic colorectal canceroxaliplatineraltitrexedsecond line treatment

Substanzen

BevacizumabraltitrexedQuinazolinesOxaliplatinFluorouracilOrganoplatinum CompoundsThiophenesLeucovorin

Autor:innen und Institutionen

  • Department of Medical oncology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier 34298 Cedex 5, France.
  • Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site de Saint Herblain 44800, France.
  • Department of Radiotherapy, Clementville Clinic, Montpellier 34070, France.
  • Department of Radiotherapy, Centre catalan d'oncologie, Perpignan 66000, France.
  • Department of Gastroenterology and Hepatology, Perpignan Hospital Center, Perpignan 66046, France.
  • Department of Clinical Research and Innovation, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier 34298 Cedex 5, France.

ORCID-Profile: Emmanuelle Samalin, Simon Thezenas, Faiza Khemissa Akouz, Catherine Fiess, Fabienne Portales, Eric Assenat, Marc Ychou, Thibault Mazard

Zitieren

APA

Samalin, E., Senellart, H., Thezenas, S., Jacquot, S., Ellis, S., Akouz, F. K., Fiess, C., Ramdani, M., Portales, F., Assenat, E., Ychou, M., Mineur, L., & Mazard, T. (2026). The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag006

Vancouver

Samalin E, Senellart H, Thezenas S, Jacquot S, Ellis S, Akouz FK, et al. The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer. The Oncologist. 2026. doi:10.1093/oncolo/oyag006

BibTeX
@article{Samalin2026,
  author = {Samalin, Emmanuelle and Senellart, Hélène and Thezenas, Simon and Jacquot, Stéphane and Ellis, Stephen and Akouz, Faiza Khemissa and Fiess, Catherine and Ramdani, Mohamed and Portales, Fabienne and Assenat, Eric and Ychou, Marc and Mineur, Laurent and Mazard, Thibault},
  title = {The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag006}
}
Kostenlos starten →